Clinical Trial Update: RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy [Phase 2, Phase 3]

View source ↗

Summary

An open-label Phase 2/3 trial to evaluate the safety and efficacy of CABA-201 in active idiopathic inflammatory myopathy and related juvenile inflammatory myopa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-synthetase Syndrome
• Dermatomyositis
• Idiopathic Inflammatory Myopathy
• Immune-mediated Necrotizing Myopathy
• Juvenile Dermatomyositis
• Juvenile Idiopathic Inflammatory Myopathy
• Juvenile Myositis
• Juvenile Polymyositis

Drugs mentioned

• CABA-201

Snippet

Sponsor: Cabaletta Bio | Conditions: Idiopathic Inflammatory Myopathy, Dermatomyositis | Phase 2, Phase 3 | Status: RECRUITING